Reiki Therapy to Improve Key Symptoms in Integrative Oncology Clinic (REIKI)

NCT ID: NCT06354049

Last Updated: 2025-11-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-08-07
• Study Completion Date: 2025-08-07

Brief Summary

The purpose of this research is to investigate the delivery of Reiki to integrative oncology patients and assess its potential for improving cancer-related symptoms in this population.

Detailed Description

Reiki is a biofield therapy originating in Japan, in which a trained practitioner places their hands on or above the body of a receiver or themselves to generate a relaxation and healing response. Systematic reviews and meta-analyses report Reiki to be effective for improving psychological and physical health symptoms. With respect to adults with cancer, Reiki has been shown to improve participants' relaxation, pain, fatigue, sleep, anxiety, stress, and wellbeing/quality of life compared to care as usual. However, one study showed no improvement in comfort and wellbeing in those receiving Reiki compared to sham Reiki control, but those receiving Reiki reported improvements above usual care.

Conditions

Cancer Pain; Oncology Pain

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

Reiki therapy

This is a feasibility single arm trial of Reiki for oncology participants.

Group Type: EXPERIMENTAL

Reiki

Intervention Type: OTHER

Reiki, originating in Japan, is a biofield therapy where a skilled practitioner places their hands on or above the body of the recipient or themselves to induce relaxation and promote healing.

Interventions

Reiki

Reiki, originating in Japan, is a biofield therapy where a skilled practitioner places their hands on or above the body of the recipient or themselves to induce relaxation and promote healing.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Age 18 - 89.
• Neoplasm diagnosis (i.e., ICD-10 C00 - D49) confirmed in electronic health record (EHR)/Caisis
• Receiving care at a UH Connor Whole Health Integrative Oncology Clinic.
• Reporting at least three ESAS symptoms ≥4/10 at baseline screening including fatigue and ≥2 other symptoms on the 9-item questionnaire.
• Able to speak and understand English.
• Has an email address, and access to a computer with internet and/or a mobile device with a functioning data plan

Exclusion Criteria

• Significant cognitive impairment that has not been corrected.
• Significant visual impairment that has not been corrected.
• Unable to provide informed consent.
• Active psychosis.
• Pregnancy.
• Metastatic disease.
• Reiki therapy within 3 months of study enrollment
• Active immunotherapy, chemotherapy, or radiation treatment, or completed within 3 months before study start. Aromatase inhibitors and tamoxifen are exceptions.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 89 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Case Comprehensive Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Santosh Rao, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center

Locations

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center

Cleveland, Ohio, United States

Countries

United States

Other Identifiers

CASE3Z24

Identifier Type: -

Identifier Source: org_study_id